48
Participants
Start Date
September 30, 2023
Primary Completion Date
May 31, 2025
Study Completion Date
May 31, 2025
TQB2928 Injection + Azacitidine for injection
"TQB2928 injection is a fully humanized Immunoglobulin G 4 (IgG4) subtype monoclonal antibody targeting CD47.~Azacitidine for injection is a nucleoside metabolism inhibitor that inhibits DeoxyriboNucleic Acid (DNA) methyltransferase, reduces DNA methylation and alters gene expression."
RECRUITING
Peking University People's Hospital, Beijing
NOT_YET_RECRUITING
The First Affiliated Hospital of China Medical University, Shenyang
NOT_YET_RECRUITING
The First Hospital of Jilin University, Changchun
RECRUITING
Shanghai Jiaotong University, School of Medicine, Ruijin Hospital, Shanghai
RECRUITING
The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou
NOT_YET_RECRUITING
The First Affiliated Hospital of Nanchang University, Nanchang
NOT_YET_RECRUITING
Chongqing Hospital of Traditional Chinese Medicine, Chongqing
NOT_YET_RECRUITING
The Third Xiangya Hospital of Central South University, Changsha
NOT_YET_RECRUITING
Henan Cancer Hospital, Zhengzhou
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY